Coming therapies: amprenavir
Related Experiment Video
Updated: Oct 18, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
1Hospital Clinic, Barcelona, Spain.
Abstract:
Amprenavir is a new peptidomimetic inhibitor of the HIV protease enzyme. Amprenavir has a twice daily dosing schedule and can be administered with or without food making it a convenient dosing regimen among the protease inhibitors (PIs). It is currently being investigated in combination with various nucleoside reverse transcriptase inhibitors (NRTIs) and initial results are promising. Amprenavir may also be useful for salvage therapy in patients failing PI-containing regimens as little cross-resistance has been observed so far with nelfinavir, indinavir or saquinavir. However, amprenavir resistant strains show cross-resistance with ritonavir. Clinical evidence indicates amprenavir is generally well tolerated. However, there is little information to date regarding the ability of amprenavir to cause lipodystrophy or other disturbances of lipid metabolism.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Antiprotozoal Agents
Drug Therapy
Antianxiety Medications
Inhibitors of Virion Maturation and Assembly
